Home > Result Summaries: Compounds > fosamprenavir > Result Summary for APV10023

Result Summary for APV10023

Result Summary

Protocol ID:	APV10023
Clinical Study ID:	APV10023
Official Title:	A Pivotal, Phase I, Open-label, Randomized, Four-Period, Single and Multiple Dose, Crossover Study to Assess the Bioequivalence of Two GW433908 700mg Oral Film-coated Tablet Variants Following Administration of Single 1400mg Doses and Following Administration of 1400mg BID for 14 Days…
Phase:	Phase 1
Study Indications or Diseases:	Infection, Human Immunodeficiency Virus
Generic Name:	fosamprenavir
Trade/Product Name:	Telzer,Telzir,Lexiva
Approved Drug Label:	http://www.gsk.com/products.html
Results Summary:	Click here to download result summary.
Citations:	Pharmacokinetics of gw433908, a prodrug of amprenavir, in healthy male volunteers. Falcoz, C., Jenkins, J. M., Bye, C., Hardman, T. C., Kenney, K. B., Studenberg, S., Fuder, H., and Prince, W. T. J Clin Pharmacol 2002; 42(8):887-98